SOCRA - Society of Clinical Research Associates The Informed Consent Process Questions and Answers

Question 1

A clinical research coordinator is consenting a potential participant for a study involving a new investigational drug. The participant is fluent in Spanish, but the IRB-approved informed consent form is only available in English. Which of the following is the most appropriate action to take?

Accepted Answer

Delay the consent process until a fully translated Spanish version of the long-form consent is approved by the IRB.

Answer

According to regulatory guidelines (21 CFR 50.20), the information given to a subject must be in a language understandable to them. While a short form process with an interpreter is permissible, the preferred and most ethically sound method is to use a fully translated and IRB-approved consent form. This ensures the participant has a written document to refer to in their own language, maximizing comprehension and respecting their autonomy. Delaying until the proper form is available upholds the highest standard of the informed consent process.

Question 2

During an informed consent discussion for a complex oncology trial, the investigator notices the potential participant is nodding along but seems overwhelmed and is not asking any questions. What is the best practice for the investigator to ensure adequate understanding?

Accepted Answer

Use a teach-back method, asking the participant to explain the study's purpose, risks, and procedures in their own words.

Answer

The informed consent process is more than a signature; it's about ensuring genuine comprehension. The teach-back method is an effective technique to assess and confirm a participant's understanding. It moves beyond simple yes/no questions and requires the participant to actively demonstrate their grasp of the key information, allowing the investigator to identify and clarify any areas of misunderstanding.

Question 3

Which of the following statements is strictly prohibited from being included in an informed consent form, according to both FDA regulations (21 CFR 50.20) and ICH GCP?

Accepted Answer

Language that appears to waive any of the subject's legal rights or releases the investigator from liability for negligence.

Answer

Both FDA regulations (21 CFR 50.20) and ICH GCP guidelines explicitly forbid the use of exculpatory language in informed consent forms. This means the document cannot include any wording that makes the participant waive or appear to waive their legal rights, nor can it release the investigator, sponsor, or institution from liability for negligence. This is a critical protection for research subjects.

Question 4

A participant signed an informed consent form for a clinical trial a year ago. The protocol has now been amended to include a new, optional blood draw for future genetic research. Which of the following actions is required?

Accepted Answer

Obtain re-consent from all active participants using an IRB-approved revised consent form that includes the new optional procedure.

Answer

When a protocol is amended with new information or procedures that might affect a participant's willingness to continue, such as an optional genetic research component, re-consent is required. The investigator must use a revised, IRB-approved informed consent form to explain the changes and document the participant's decision to agree to the new procedures or continue under the terms of the original consent.

Question 5

An investigator is conducting a trial that involves collecting identifiable biospecimens. According to the Revised Common Rule (45 CFR 46), which of the following is a new required element that must be included in the informed consent form?

Accepted Answer

A statement on whether the subject's de-identified biospecimens may be used for future research.

Answer

The Revised Common Rule (also known as the 2018 Requirements) introduced a new basic element of informed consent. For research involving the collection of identifiable private information or identifiable biospecimens, the consent form must include a statement that the identifiers might be removed and the information or biospecimens could be used for future research, or a statement that they will not be used for future research.

(SOCRA) Society of Clinical Research Associates Practice Test

(SOCRA) Society of Clinical Research Associates Practice Test

SOCRA - Society of Clinical Research Associates The Informed Consent Process Questions and Answers